HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2004
Business Overview: The Company designs, manufactures, and sells instruments, devices, and consumables for research laboratories, primarily serving pharmaceutical, biotechnology, and academic sectors. Growth strategy relies on new product development, strategic partnerships, and acquisitions. Approximately 46% of revenues for the nine months ended September 30, 2004, were derived from non-U.S. operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 10% ($2.1M) for the quarter and 8% ($4.9M) for the nine months compared to the prior year. Growth was driven primarily by the acquisitions of Hoefer and KD Scientific and favorable foreign currency exchange rates (strengthening of the British pound and Euro).
• Profitability Decline: Net income for the nine months ended September 30, 2004, decreased 52% to $1.2 million from $2.5 million in the prior year. Operating income dropped 51% to $2.5 million.
• Expense Increases: General and administrative expenses rose 22% year-over-year due to restructuring charges ($0.6M) and Sarbanes-Oxley compliance costs. Interest expense increased significantly due to higher debt levels used to fund acquisitions.
• Segment Performance: Sales at the Genomic Solutions subsidiary decreased by approximately $5.0 million for the nine-month period, negatively impacting overall results.

Guidance, Outlook, and Risks

• Outlook: Management expects organic revenue growth in 2004 to be below historic levels without further acquisitions. The Company anticipates revenues from genomics, proteomics, and high-throughput screening product lines will be lower in 2004 than in 2003 due to market uncertainty and a lack of focus in the first half of the year.
• Liquidity and Capital: The Company has a $20 million credit facility with Brown Brothers Harriman, with approximately $17.7 million drawn as of September 30, 2004. Management believes current resources are sufficient for at least 12 months. However, the Company is currently prohibited from accessing public equity markets due to a delinquent Form 8-K amendment, limiting capital raising to private transactions or additional borrowing.
• Restructuring: The Company recorded $0.6 million in restructuring charges related to Genomic Solutions and Biochrom to realign business strategy and close facilities.
• Legal Contingency: An arbitration proceeding initiated by Paul D. Grindle regarding the 1996 purchase of Harvard Apparatus is pending appeal in the Massachusetts Appeals Court. The Company previously prevailed in the arbitration and Superior Court.
• Key Risks: Significant exposure to the cyclical capital equipment market; dependence on GE Healthcare for distribution of certain products (approx. 17% of revenue); and potential impairment of goodwill ($41.5 million) if acquired businesses underperform.

Investor Verification Checklist

• Capital Access: Verify the status of the outstanding Form 8-K amendment and the timeline for regaining access to public equity markets (Form S-3 eligibility).
• Debt Covenants: Confirm continued compliance with financial covenants in the $20 million credit facility, specifically regarding income, debt coverage, and working capital.
• Genomic Solutions Turnaround: Monitor the effectiveness of the restructuring plan at Genomic Solutions and its ability to return to profitability.
• Acquisition Integration: Assess the integration progress and revenue contribution of recent acquisitions (KD Scientific, Hoefer) versus the decline in legacy segments.
• Legal Exposure: Track the outcome of the Grindle appeal, which involves a potential claim of $15 million in stock value.